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Background: The most interesting recent development in transplantation immunobiology is the clinical
implementation of tolerance induction. We report our experience of megadose hematopoietic stem cell
transplantation with non-myeloablative minimum conditioning in renal allograft recipients.
Methods: This was a retrospective, single-center study of 159 renal allograft biopsies from two groups of
patients: one group underwent a tolerance induction protocol (TIP) before renal transplantation; the other
underwent renal transplantation directly. Biopsies were classified into two subgroups to differentiate between
acute and late rejection: 127 biopsies, comprising 64 from patients who underwent a TIP and 63 from controls,
performed within 180 days after transplantation; and 32 biopsies, comprising 26 from patients who under-
went a TIP and six from controls, performed 180 days after transplantation. All patients received cyclosporine
7 mg/kg/day, tapered to 3 mg/kg/day 3 months after transplantation, and subsequently continued at the latter
dosage.
Results: There was markedly less immunologic injury (i.e. generally fewer and milder rejection episodes)
evident in biopsies from patients who underwent TIP than in biopsies from controls. Cyclosporine toxicity was
considerably greater in patients from the TIP versus control group (82.9% vs 40.6%).
Conclusion: TIP protects renal allografts from immunologic injury and has an unexplained cyclosporine-
sparing effect. [Hong Kong J Nephrol 2005;7(1):22–6]
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Tolerance induction in renal transplantation
INTRODUCTION
Over the last 50 years, transplantation science has
progressed such that transplantation has become an
acceptable therapeutic option for patients with end-
stage renal disease. However, post-transplant immuno-
suppressive drug therapy, which is essential for sur-
vival of these patients, has serious risks in the form of
infections, malignancies, and direct toxicity leading to
chronic graft dysfunction. Cyclosporine is a very po-
tent immunosuppressive drug that has time- and dose-
dependent effects; paradoxically, it has been observed
that cyclosporine toxicity can lead to chronic graft
dysfunction. During low-dose immunosuppressive
therapy, we have observed stable, adequate graft
function, with a significantly lower incidence of re-
jection episodes than with high-dose therapy [1–4].
We report our experience of renal transplantation in
patients who willingly underwent tolerance induction
protocol (TIP) using megadose hematopoietic stem
cell transplantation (HSCT), which aimed to reduce




This was a retrospective study of 159 renal allograft
biopsies performed between January 1, 2003 and
December 31, 2003. The biopsies were obtained from
two groups of patients: those who willingly underwent
TIP with HSCT before renal transplantation; and those
who underwent direct renal transplantation, and who
thus served as a control group. Patients were enrolled
in the TIP after giving informed consent in line with a
modified Helsinki declaration. Patients were classified
into two groups to differentiate between acute and late
rejection: 127 patients who underwent biopsy within
180 days after transplantation; and 32 patients who un-
derwent biopsy 180 days after transplantation. While
the indication for performing biopsies was unex-
plained, all patients had a sustained rise in serum cre-
atinine level of > 10% from baseline. The demographic
profile for both groups was fairly balanced in the ear-
ly graft dysfunction period (Table 1). In patients in the
TIP group who underwent biopsy 180 days after
transplantation, one patient who had a transplant in
March 1999, and four who had a transplant in 2000,
underwent TIP without thymic inoculation. All other
patients in the TIP group underwent the protocol
described below.
Tolerance induction protocol
Intrathymic renal tissue transplantation
Most patients in the TIP group received donor-renal
tissue after a negative lymphocytotoxicity cross-
matching (LCM) test. The mean weight of renal tissue
was 600 +g, and the mean total number of glomeruli
was 12. Tissue was procured using a standard kidney
biopsy procedure under local anesthesia, and was then
injected into the recipient thymus, for which a 4 cm
long incision was made into the right second intercostal
space under general anesthesia. After cutting all the
muscles, the mediastinal fascia was opened and the
thymus identified in the retrosternal space. Then,
minced renal tissue was introduced with a 20-gauge
needle. Hemostasis was checked and the wound closed.
Hematopoietic stem cell mobilization, collection,
infusion and injection techniques
Donors received subcutaneous granulocyte colony-
stimulating factor 10 +g/kg/day for 2 days, after which
bone marrow aspiration was performed, under seda-
tion and local anesthesia, from the posterior superior
iliac crest on day 3. From 500 mL of aspirated, un-
fractionated bone marrow, 100 mL was introduced into
the sternal bone marrow of the recipient, and 200 mL
each was infused into the portal and peripheral
circulation under general anesthesia after cytoreduc-
tion. Subsequently, donors were twice subjected to
leukophoresis using a stem cell separator (Haemo-
netics® MCS® 3p; Haemonetics Corp, Braintree,
MA, USA), and peripheral blood stem cells (PBSC)
were collected and immediately infused in unmodi-
fied form into the periphery of recipients, who had
their CD34+ and total cell counts determined. The mean
bone marrow CD34+ cell count was 1.2% (yield, 1.2 =
108 cells/kg body weight), whereas the mean PBSC
CD34+ cell count was 0.9% (yield, 24.2 = 108 cells/
kg). Transplantation surgery was carried out 6 days af-
ter the last PBSC infusion, after a negative LCM test.
Human leukocyte antigen (HLA) typing and LCM
HLA typing and LCM were performed at the begin-
ning and end of the TIP using conventional serologic
techniques (one-Lambda pre-dot trays were used for
HLA-A, -B, and -DR typing using automatic cross-
match, dithiothretol, and standard cytotoxicity methods
with mixed-cell populations). T- and B-lymphocytes
were used separately for cross-matching, and donor-
specific positivity was found with mixed-cell popula-
tions. Control group patients underwent transplanta-
tion after a negative LCM test.
Recipient immunosuppression
Cyclosporine was the principal immunosuppressant
used for all groups. Initially, the dosage was 7 mg/kg/
day, which was tapered to 3 mg/kg/day 3 months after
transplantation and continued at this level thereafter.
The aim was to maintain trough blood levels at around
130 ( 20 ng/mL during the first 3 months after trans-
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plantation, and at about 100 ( 20 ng/mL thereafter.
Cyclosporine levels were measured with an enzyme-
multiplied immunoassay technique (EMIT) 2000
cyclosporine-specific assay system (Syva® Co, Dade
Behring Inc, Deerfield, IL, USA). Prednisolone 0.5 mg/
kg/day was administered for the first month after
transplantation, followed by 0.2 mg/kg/day in the TIP
group. Azathioprine 2 mg/kg/day was added as a third
drug after acute rejection episodes, but was replaced
by mycofenolate mofetil whenever toxicity was ob-
served. Control patients were maintained on standard
triple-drug immunosuppressant schedules.
Histopathologic examination
The biopsies were performed on 3 +m thick paraffin
sections and were stained with hematoxylin and eo-
sin, periodic acid-Schiff, Gomori’s trichrome, and
methaneamine-silver stains. The biopsies were in-
dependently evaluated by three different pathologists,
and reports were made after consensus was reached.
Rejection was diagnosed as per modified Banff
classification [5].
RESULTS
Biopsy < 180 days after transplantation
In the TIP group, 32 (50%) biopsies revealed acute
cyclosporine toxicity, with changes of toxic tubu-
lopathy, showing isometric vacuolization in most
proximal tubules, and arteriolopathy with segmental,
subintimal hyalinosis in all of them (Figure 1). Tubular
microcalcification was seen in only two biopsies. The
incidence of acute cyclosporine toxicity was less in
controls, with 26 biopsies (41.3%) showing similar
changes. The other pathologic changes were acute
tubular necrosis, acute tubulointerstitial rejection
(which was borderline or mild in the TIP group vs
moderate to severe [type-IA/B toxicity] in the control
group), acute vascular rejection (type IIA), and
recurrent or de novo glomerulopathy (Table 2). Six of
32 biopsies (18.8%) with acute cyclosporine toxicity
in the TIP group also showed acute borderline tubu-
lointerstitial rejection with acute tubular necrosis, and
one biopsy (3.1%) revealed acute tubulointerstitial
rejection (type IA). Two of 26 biopsies (7.7%) with
acute cyclosporine toxicity in the control group revealed
acute tubulointerstitial rejection (type IB).
Trough blood cyclosporine levels were not
significantly different between the TIP and control
groups: TIP patients had a mean cyclosporine trough
level of 130 ( 15 ng/mL, with a mean dosage of 3.5 (
0.5 mg/kg/day, whereas patients in the control group
had a mean cyclosporine trough level of 130 ( 10 ng/mL,
with a mean dosage of 4.5 ( 0.5 mg/kg/day. Changes
indicating chronic cyclosporine toxicity were observed
in the form of tubular atrophy, periglomerular fibrosis,
and focal interstitial fibrosis: four TIP biopsies (6.3%)
and two control biopsies (3.2%) showed these changes.
In addition, cyclosporine-induced hemolytic uremic
syndrome (HUS) was evident in two TIP biopsies
Table 1. Patient demographic data
Biopsy Gender (M:F) Age, yr (range) Biopsy period, d Mean SCr level,(range) mg/dL (range)
Biopsies performed < 180 days after transplantation
TIP (n = 64) 54 : 10 33.5 (15–58) 29.9 (0–126) 2.52 (0.9–5.6)
Control (n = 63) 51 : 12 36.4 (16–54) 26.5 (0–176) 2.78 (0.9–7.5)
Biopsies performed 180 days after transplantation
TIP (n = 26) 22 : 4 35 (14–55) 614 (210–1,580) 2.49 (1.15–4.71)
Control (n = 6) 6 : 0 24.3 (15–39) 537 (304–1,100) 4.01 (2.39–5.2)
SCr = serum creatinine; TIP = tolerance induction protocol.
Figure 1. Cyclosporine-induced toxic arteriolopathy, tubulopathy,
and thrombotic microangiopathy, showing mesangiolysis and
platelet thrombi in glomerular capillaries, together with acute border-
line tubulointerstitial rejection (periodic acid-Schiff stain; = 200).
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Tolerance induction in renal transplantation
(2.7%) and one control biopsy (1.6%) (Figure 2).
In the TIP group, the mean serum creatinine level
of 2.45 mg/dL at the time of biopsy (which revealed
acute cyclosporine toxicity) dropped significantly to
1.68 mg/dL (p = 0.0003) 1 month after tapering the
cyclosporine dosage; corresponding values in the con-
trol group were 2.69 mg/dL and 2.1 mg/dL (p = 0.02).
Biopsy 180 days after transplantation
Acute cyclosporine toxicity was noted in 16 TIP bi-
opsies (61.5%), including two showing cyclosporine-
induced HUS. Two TIP biopsies (7.7%) showed acute
tubular necrosis; five TIP biopsies (19.2%) and four
control biopsies (66.6%) revealed mild acute tubulo-
interstitial rejection (type IA), with underlying chronic
cellular rejection with chronic transplant glomerulo-
pathy; acute tubulointerstitial rejection (type IA) was
noted in six TIP biopsies (23.1%); changes indicating
chronic cyclosporine toxicity were evident in six TIP
biopsies (23.1%) and two control biopsies (33.3%); and
recurrent glomerulopathy (pauci-immune crescentic
glomerulonephritis) was noted in one TIP biopsy
(3.8%) (Table 2).
In the TIP group, the mean serum creatinine level of
2.32 mg/dL at the time of biopsy dropped to 2.12 mg/dL
1 month after tapering the cyclosporine dosage; cor-
responding values in the control group were 4.3 mg/dL
and 2.72 mg/dL (p < 0.5 in both groups).
Entire study population
When the cyclosporine dosage was tapered, there was
a statistically significant recovery of allograft function
in the form of lower serum creatinine levels. The overall
incidence of cyclosporine toxicity was 64.4% in the
TIP group (58/90 biopsies) and 40.6% in the control
group (28/69 biopsies), but the difference was not
statistically significant.
Trough blood cyclosporine levels of 300 ( 20 ng/mL
were attained at a dosage of 3 mg/kg/day in TIP
recipients, and at a dosage of 5 mg/kg/day in controls,
throughout the post-transplantation period. No
correlation was observed between trough cyclosporine
level and tissue toxicity. However, acute cyclosporine
nephrotoxicity was observed even at a trough blood
level of 110 ng/mL (recommended level 76–150 ng/
mL). Further, one of the most interesting, unexplained
observations in TIP recipients versus controls was the
attainment of adequate trough blood levels at lower
cyclosporine doses.
DISCUSSION
When cyclosporine was introduced in 1981, a
multicenter trial had demonstrated 1-year actuarial
survival of 72% in cyclosporine recipients, compared
with 52% in control patients receiving corticosteroids
and azathioprine; after 5 years, graft survival was 55%
in the cyclosporine group and 40% in the control group
[6]. Moreover, cyclosporine nephrotoxicity is more
likely to occur in kidneys that have incurred ischemia
reperfusion injury [7], and corticosteroids were unable
Table 2. Histopathologic profile of biopsies; data shown are n (%) of biopsies
< 180 days after transplantation 180 days after transplantation
TIP (n = 64) Control (n = 63) TIP (n = 26) Control (n = 6)
Acute cyclosporine toxicity 32 (50) 26 (41.3) 16 (61.5) 0
Acute tubular necrosis 22 (34.4) 20 (31.8) 2 (7.7) 0
Acute tubulointerstitial rejection (type IA/B) 19 (29.7) 41 (65.1) 5 (19.2)* 6 (100)*
Acute tubulointerstitial rejection (type IA) – – 6 (23.1) 0
Acute vascular rejection (type IIA) 4 (6.3) 21 (33.3) – –
Chronic cyclosporine toxicity 4 (6.3) 2 (3.2) 6 (23.1) 2 (33.3)
Recurrent/de novo glomerulopathy 3 (4.7) 2 (3.2) 1 (3.8) 0
*Also includes chronic cellular rejection and chronic transplant glomerulopathy. TIP = tolerance induction protocol.
Figure 2. A biopsy from a patient in the control group, showing
acute vascular rejection (type IIA) and acute tubulointerstitial
rejection (type IB) (hematoxylin & eosin stain; = 200).
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to protect the allografts from cyclosporine nephro-
toxicity, which was confirmed by renal allograft bi-
opsy 1 year after transplantation.
A pathologic diagnosis of cyclosporine toxicity was
made in 61% of an early series, and in 38% of biopsies
almost a decade later [8]. Cyclosporine estimation has
to be standardized at each center. Generally, optimal
trough cyclosporine levels in whole blood in the first 3
months after transplantation are considered to be 150–
250 ng/mL; after the first 3 months, it is desirable to
maintain the lower range of 100–200 ng/mL [9].
Our transplantation tolerance induction model is
based on apoptotic deletion of peripheral T cells and
the establishment of persistent mixed hematopoietic
chimerism. It is difficult to quantify the total T cell range
and its deletion. We presume that a decrease in total
major histocompatibility complex-restricted T cell mass
may have some bearing on a significant reduction in
the number and intensity of rejections in such TIP
patients. This may also have led to changes in
cyclosporine pharmacokinetics, thus leading to better
cyclosporine absorption in TIP recipients versus
controls, and there were no identifiable risk factors for
cyclosporine toxicity other than the TIP.
In summary, our experience with TIP using
megadose HSCT in renal allograft recipients showed
less immunologic injury to grafts, and a cyclosporine-
sparing effect, relative to findings noted in control
patients.
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